Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

primary analysis of Phase ib trial of duvelisib for cytokine release syndrome prophylaxis in patients undergoing chimeric antigen receptor T cell therapy for non-hodgkins lymphoma

Michael Slade, Michael Rettig, Parmeshwar Amatya, Zachary Crees, Brad Kahl, Neha Mehta-Shah, Dilan Patel, David Russler-Germain, Nancy Bartlett, Amanda Cashen, Iskra Pusic, Geoffrey Uy, John DiPersio, Armin Ghobadi

Blood (2025) 146 (Supplement 1): 929.

https://doi.org/10.1182/blood-2025-929

Published: 2025

Journal Articles

Non-invasive classification & molecular subtyping of mature lymphoid neoplasms by cell-free DNA profiling

Blood (2025) 146 (Supplement 1): 5330.

https://doi.org/10.1182/blood-2025-5330

Published: 2025

Journal Articles

Allogeneic stem cell transplant results in t-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort

Blood (2025) 146 (Supplement 1): 1054.

https://doi.org/10.1182/blood-2025-1054

Published: 2025

Journal Articles

Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis

Blood (2025) 146 (Supplement 1): 893.

https://doi.org/10.1182/blood-2025-893

Published: 2025

Journal Articles

Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma

David Russler-Germain, Hunter Cochran, Fei Wan, Amalia Dubois, Chaz Moreno, Francesca Loyet, Dilan Patel, Brad Kahl, Todd Fehniger, Amanda Cashen, Armin Ghobadi, Neha Mehta-Shah, Nancy Bartlett

Blood (2025) 146 (Supplement 1): 5508.

https://doi.org/10.1182/blood-2025-5508

Published: 2025

Journal Articles

PET imaging biomarkers predict survival in peripheral T-cell lymphoma: A systematic review and meta-analysis.

Lohitha Dhulipalla, Tapasya Raavi, Meghana Pattipati, Kai Wang, Monika Karki, Sihle Mabhida, Luis Malpica, Ranjit Nair, Luis Fayad, Neha Mehta-Shah, Ranjana Advani, Kerry Savage, Steven Horwitz, Maria Rodriguez, F. B. Hagemeister, Swami Iyer

Blood (2025) 146 (Supplement 1): 6299.

https://doi.org/10.1182/blood-2025-6299

Published: 2025

Journal Articles

Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma: Final results from the phase 2 PRIMO trial - impact of prior therapy and expanded safety analysis

Pier Luigi Zinzani, Neha Mehta-Shah, Jasmine Zain, Giuseppe Gritti, Lauren Pinter-Brown, Koji Izutsu, Ohad S. Bentur, David Sidransky, Jonathan Brammer, Barbara Pro, Christopher Fox, Steven Horwitz

Blood (2025) 146 (Supplement 1): 3634.

https://doi.org/10.1182/blood-2025-3634

Published: 2025

Journal Articles

A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study

Nikita Dave, Imran Nizamuddin, Neha Mehta-Shah, Edd Ricker, Jennifer Amengual, Robert Baiocchi, Timothy Voorhees, Stefan Barta, Jordan Carter, Elise Chong, Michael Cook, Daniel Landsburg, Stephen Schuster, Colin Thomas, Emily Tomasulo, Jakub Svoboda, Sunita Dwivedy Nasta

Blood (2025) 146 (Supplement 1): 1963.

https://doi.org/10.1182/blood-2025-1963

Published: 2025

Journal Articles

Diagnostic and therapeutic patterns in cutaneous T-cell lymphomas (CTCL): Real-world data from the lymphoma epidemiology outcome-molecular epidemiology resource (LEO-MER) prospective cohort study.

Muhammad Saad Hamid, Ashley McCook-Veal, Jeffrey Switchenko, Neha Mehta-Shah, Neha Akkad, Luis Malpica, Danielle Wallace, Evelyn Orlando, Jia Ruan, Brooj Abro, Melissa Larson, James Cerhan, Christopher Flowers, Georgios Pongas, Eric Mou, N. Nora Bennani, Pamela Allen

Blood (2025) 146 (Supplement 1): 1870.

https://doi.org/10.1182/blood-2025-1870

Published: 2025

Journal Articles

Favorable safety and efficacy in a phase II trial using duvelisib maintenance after autologous stem cell transplant in T-cell and B-cell non-Hodgkin lymphomas

Hunter Cochran, Raya Saba, Ningying Wu, Neha Mehta-Shah, Armin Ghobadi, John DiPersio, Amanda Cashen

Blood (2025) 146 (Supplement 1): 1860.

https://doi.org/10.1182/blood-2025-1860

Published: 2025

Journal Articles

Shorter diagnosis to treatment interval is associated with poor prognosis in patients with peripheral T-cell lymphoma: Analysis from the LEO and MER cohorts

Blood (2025) 146 (Supplement 1): 5439.

https://doi.org/10.1182/blood-2025-5439

Published: 2025

Journal Articles

A multicenter real-world analysis (RWA) of primary cutaneous anaplastic large cell lymphoma (PCALCL) treated in the era of targeted therapies

Deepa Jagadeesh, Stefan Barta, Seunghee Margevicius, Jonathan Brammer, Jeanette Comstock, Pingfu Fu, Rahul Mishra, Montreh Tavakkoli, Alma Habib, Imran Nizamuddin, Tiffany Chang, Melissa Pulitzer, Cesar Virgen, Sharina Macapagal, Madiha Iqbal, N. Nora Bennani, Frederick Lansigan, Neha Mehta-Shah, Zachary Epstein-Peterson

Blood (2025) 146 (Supplement 1): 5433.

https://doi.org/10.1182/blood-2025-5433

Published: 2025

Journal Articles

Patterns of care in second line management of nodal peripheral T-cell lymphoma from the lymphoma epidemiology of outcomes (LEO) and molecular epidemiology resource (MER) prospective cohort Study

Blood (2025) 146 (Supplement 1): 3635.

https://doi.org/10.1182/blood-2025-3635

Published: 2025

Journal Articles

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

Blood blood.2025028848.

https://doi.org/10.1182/blood.2025028848

Published: 2025

Journal Articles

Peripheral T-cell lymphoma: are all patients high risk?

Lauren Shea, Neha Mehta-Shah

Blood (2024) 144 (25): 2604–2612.

https://doi.org/10.1182/blood.2023020912

Published: 2024

Journal Articles

Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)

Alvaro J Alencar, Olivia Bobek, Neha Mehta-Shah, Narendranath Epperla, Christine Lu-Emerson, Sarah C. Rutherford, Adam J. Olszewski, Thomas Ollila, Samuel Singer, Travis Dockter, Susan M. Geyer, Lori Rosenstein, Macarena De La Fuente, Eric D. Hsi, Shira N. Dinner, James L. Rubenstein, Nancy L. Bartlett, John P. Leonard

Blood (2024) 144 (Supplement 1): 4502.4.

https://doi.org/10.1182/blood-2024-209238

Published: 2024

Journal Articles

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

Christopher J. Forlenza, Opeyemi Jegede, Stephen M. Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E. Amengual, Peter D. Cole, Brad S. Kahl, Catherine S. Diefenbach

Blood (2024) 144 (Supplement 1): 4427.

https://doi.org/10.1182/blood-2024-201624

Published: 2024

Journal Articles

A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma

Swaminathan P Iyer, Ranjit Nair, Neha Mehta-Shah, Don A. Stevens, Alessandra Tucci, Antonio Pinto, Pier Luigi Zinzani

Blood (2024) 144 (Supplement 1): 4449.

https://doi.org/10.1182/blood-2024-209340

Published: 2024

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial

Neha Mehta-Shah, Pier Luigi Zinzani, Eric D. Jacobsen, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Ohad S Bentur, David Sidransky, Jonathan E. Brammer, Barbara Pro, Christopher P. Fox, Steven Horwitz

Blood (2024) 144 (Supplement 1): 3061.

https://doi.org/10.1182/blood-2024-203577

Published: 2024

Journal Articles

Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)

Jia Ruan, Evelyn H. Orlando, Alison Moskowitz, Zhengming Chen, Neha Mehta-Shah, Lubomir Sokol, Steven Horwitz, Sarah C. Rutherford, Tejasvi Sahni, Ari M Melnick, Giorgio Inghirami, Leandro Cerchietti, John P. Leonard, Peter Martin

Blood (2024) 144 (Supplement 1): 1693.

https://doi.org/10.1182/blood-2024-206606

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

primary analysis of Phase ib trial of duvelisib for cytokine release syndrome prophylaxis in patients undergoing chimeric antigen receptor T cell therapy for non-hodgkins lymphoma

Non-invasive classification & molecular subtyping of mature lymphoid neoplasms by cell-free DNA profiling

Allogeneic stem cell transplant results in t-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort

Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis

Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma

PET imaging biomarkers predict survival in peripheral T-cell lymphoma: A systematic review and meta-analysis.

Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma: Final results from the phase 2 PRIMO trial - impact of prior therapy and expanded safety analysis

A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study

Diagnostic and therapeutic patterns in cutaneous T-cell lymphomas (CTCL): Real-world data from the lymphoma epidemiology outcome-molecular epidemiology resource (LEO-MER) prospective cohort study.

Favorable safety and efficacy in a phase II trial using duvelisib maintenance after autologous stem cell transplant in T-cell and B-cell non-Hodgkin lymphomas

Shorter diagnosis to treatment interval is associated with poor prognosis in patients with peripheral T-cell lymphoma: Analysis from the LEO and MER cohorts

A multicenter real-world analysis (RWA) of primary cutaneous anaplastic large cell lymphoma (PCALCL) treated in the era of targeted therapies

Patterns of care in second line management of nodal peripheral T-cell lymphoma from the lymphoma epidemiology of outcomes (LEO) and molecular epidemiology resource (MER) prospective cohort Study

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

Peripheral T-cell lymphoma: are all patients high risk?

Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial

Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only